AFFILIATIONS
1 EBMT Complications Working Party, Paris, France, KU Leuven, Leuven, Belgium, University Hospitals Leuven, Leuven, Belgium
2 EBMT Complications Working Party, Paris, France
3 EBMT Complications Working Party, Paris, France
4 University Hospital Eppendorf, Hamburg, Germany
5 University Hospital Essen, Essen, Germany
6 Medizinische Klinik m. S. Hamatologie, Onkologie und Tumorimmunologie, Berlin, Germany
7 Hannover Medical School, Hannover, Germany
8 Saint-Louis Hospital, BMT Unit, AP-HP, Université Paris Cité, Paris, France
9 Programme de Transplantation & Therapie Cellulaire, Marseilles, France
10 Oslo University Hospital,, Oslo, Norway
11 CHU Bordeaux, Hopital Haut-Leveque, Pessac, France
12 University of Freiburg, Freiburg, Germany
13 University of Heidelberg, Heidelberg, Germany
14 HUCH Comprehensive Cancer Center, Helsinki, Finland
15 University Hospital Basel, Basel, Switzerland
16 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
17 University Hospital Zurich, Zurich, Switzerland
18 CHU Institut Universitaire du Cancer Toulouse, Toulouse, France
19 Department of Hematology, Rijeka University Hospital Centre, Faculty of Medicine, University of Rijeka, Rijeka, Croatia, EBMT Complications Working Party, Paris, France
20 Comprehensive Cancer Centre, King's College London, London, United Kingdom, EBMT Complications Working Party, Paris, France, King's College Hospital, London, United Kingdom
21 EBMT Complications Working Party, Paris, France, Institut Catalá d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain
22 EBMT Complications Working Party, Paris, France, RM Gorbacheva Research Institute, Pavlov University, St Petersburg, Russian Federation
23 Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, EBMT Complications Working Party, Paris, France
24 Charité-CVK, University Medicine Berlin, Berlin, Germany, EBMT Complications Working Party, Paris, France
ABSTRACT
Introduction
Post Hematopoietic Stem Cell Transplantation Cyclophosphamide (PTCY) GVHD prophylaxis is becoming more popular since several studies suggest superior medium-term outcomes compared with more traditional prophylaxis regimens, such as anti-thymoglobulin (ATG), in the context of allogeneic hematopoietic transplantation (HCT). However, cyclophosphamide toxicity might negatively impact long-term HCT outcome. We therefore used the EBMT registry to compare the outcome of patients receiving grafts from HLA-matched related donors (MRD), 10/10 matched unrelated donors (MUD) and 9/10 mismatched unrelated donors (MMUD) after undergoing either ATG- or PTCY-based GVHD prophylaxis among long-term survivors.
Methods
All adult patients reported to the EBMT database as having received a MRD, MUD or MMUD for any hematological malignancy other than plasma cell disorders were analyzed provided they had received a first allogeneic HCT using peripheral blood stem cells between January 1, 2014, and December 31, 2020 using either ATG or PTCY, and they had survived at least 2 years without relapse after HCT. Patients with any subsequent allogeneic HCT in the first two years were excluded. A 2-year landmark analysis was performed for major transplantation outcomes (overall survival (OS), progression free survival (PFS), relapse and non-relapse mortality (NRM)), as well as a Cox multivariate analysis to evaluate the adjusted impact of the ATG or PTCY GVHD prophylaxis regimen. Three separate analyses were carried out, one for each type of donor.
Results
A total of 11 857 long-term survivors with a follow-up of at least 33 months after HCT were analyzed, of these 10 540 (89%) and 1317 (11%) had received ATG or PTCY respectively, with 2856 MRD (24%), 7189 MUD (61%) and 1812 MMUD (15%) as the donor source. The 5-year post-HCT OS was close to 90% for all donor types, regardless of GVHD prophylaxis regimen, with comparable adjusted hazard ratios (HR) of 0.72 (p=0.16), 1.19 (p=0.44) and 1.26 (p=0.41) for MRD, MUD and MMUD respectively. Similarly, the 5-year PFS was above 80%, with no significant differences in HR: 0.85 (p=0.39), 1 (p=0.98) and 0.94 (p=0.77) for MRD, MUD and MMUD respectively. The five-year relapse incidence was around 10% regardless of prophylaxis regimen (HR: 1.05 (p=0.82), 0.99 (p=0.98) and 0.82 (p=0.39) for MRD, MUD and MMUD respectively). For MUD and MMUD, no significant difference in NRM at 5 years was seen (HR: 0.99 (p=0.97) and 1.36 (p=0.44) respectively). In the MRD setting, the 5-year NRM was 4.2% after ATG compared with 5.1% after PTCY, with an adjusted HR of 0.53 (95% confidence interval: 0.29-0.99; p=0.046). No signal for a particular toxicity profile was seen in causes of death, with relapse being responsible for the majority of long-term fatal outcomes across donor types.
Conclusion
HCT patients who have survived two years without relapse after receiving ATG or PTCY as GVHD prophylaxis have excellent long-term outcomes with low risks of subsequent long-term relapse or death, approximatively 10% each. No significant outcome differences were seen between long-term survivors having received ATG or PTCY, except for a borderline significant lower risk of NRM when ATG was used in the MRD setting. Considering the retrospective nature of the data, future studies are required to confirm these promising results and ascertain the lack of long-term toxicity of using PTCY.
DISCLOSURES
Hélène M Schoemans, MD, PhD: Incyte, Novartis, MAAT Pharma, Mallinckrodt Pharmaceuticals, Sanofi, BeiGene, OrcaBio and the Belgian Hematological Society (BHS) - Honoraria; Sanofi, Pfizer, Abbvie, EBMT, IACH, CIBMTR - Research Funding; Incyte, Novartis, MAAT Pharma, Mallinckrodt Pharmaceuticals, Sanofi, BeiGene, OrcaBio and the Belgian Hematological Society (BHS) - Consultancy (Includes expert testimony)